Pyxis Oncology, Inc. (PYXS)

Nasdaq: PYXS · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2019

Full chart Alerts Compare

Grade4.6

◀ Past 5.6● Present 3.3▶ Future 5.1

4 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Pyxis Oncology, Inc.

Nine metrics read from its own filings, by tense

Headline grade

4.6/10

◀ Past5.625% of the headline

● Present3.335% of the headline

▶ Future5.140% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 5 read as filed from the record and 4 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

5.6/1025% of the headline grade · 1 of 3 filed, 2 estimated

Surviving crises

as filed

8.2/10

Has it survived what it has been through?

No warning events in its filings since 2019.

weight 22% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

Pyxis Oncology, Inc.'s filings since 2019 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

SI estimate

5.1/10

What has it actually done, year after year?

SI estimate 5.1/10, confidence 20 of 100 (family median).

weight 45% of this tense · 50th percentile among 324 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate: Fewer than three filed years of revenue on file, so the desk assumes the typical reading of its industry family, the median of 324 members with one.
What the record cannot read: Fewer than three filed years of revenue on file.
How it was reasoned: family median, 324 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Pyxis Oncology, Inc.'s track record is put at 5.1 of 10 with a confidence of 20 of 100, because fewer than three filed years of revenue on file, so the desk assumes the typical reading of its industry family, the median of 324 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Shareholder treatment

SI estimate

4.6/10

How has it treated the people who own it?

SI estimate 4.6/10, confidence 35 of 100 (one part).

weight 33% of this tense · 46th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 46% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Pyxis Oncology, Inc.'s shareholder treatment is put at 4.6 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 46% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.3/1035% of the headline grade · 3 of 3 filed

Financial health

as filed

4.2/10

Is it financially healthy right now?

ROE -149%: lost 149¢ per shareholder dollar. Leverage 42%: owes 42¢ per asset dollar.

weight 45% of this tense · 42nd percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Pyxis Oncology, Inc. lost about 149 cents for every dollar of shareholders' money, and gross profitability: its products earned about 13 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 42 cents per dollar of assets, and net share issuance: its share count grew 6.3% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 42% of its family
return on equitybottom 22% of its family
gross profit against assetsbottom 35% of its family
the share count against the year beforetop 32% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

3.5/10

How strong is its position in its industry?

bottom 35% of 315 in its family; net margin -574.5%.

weight 22% of this tense · 35th percentile among 315 sector filers · read for its customers

From the record

Pyxis Oncology, Inc.'s standing among 315 graded names in its industry family: revenue of $14 million in fiscal 2025 ranks in the bottom 45% by size; a net margin of -574.5% ranks in the bottom 35%; revenue growth of -14.2% a year over the last 1 filed years ranks in the bottom 24% (its annual reports).

What it rests on

revenue against the family$13.9Mbottom 45% of its family
net margin-574.5%bottom 35% of its family
three-year revenue growth-14.2%bottom 24% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed

2.0/10

What are the people in charge doing?

bottom 20% of 315 in its family for leadership; chief executive since 2026.

weight 33% of this tense · 20th percentile among 315 sector filers · read for its shareholders

From the record

Pyxis Oncology, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Civik, Thomas (CEO & Chairman of the Board, as filed), filing under that title since 2026-02-05, 9 months (bottom 12% of its family); the 9 officers and directors filing in the last fifteen months have been on the record a median of 4.3 years (bottom 27%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 9 people in charge now (bottom 21%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

officer and director changes on Form 8-K, against the people in charge7 in three years among 9 peoplebottom 21% of its family
the median years the people in charge have filed4.3 yearsbottom 27% of its family
the chief executive's years on the record10 monthsbottom 12% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

5.1/1040% of the headline grade · 1 of 3 filed, 2 estimated

Room to expand

as filed

5.3/10

How much room does it have to grow?

top 47% of 273 in its family for room to expand.

weight 33% of this tense · 53rd percentile among 273 sector filers · read for itself

From the record

Pyxis Oncology, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $15 million against no long-term debt tagged leaves 16.9% of its assets as net cash, bottom 34% of its family; cash from operations less capital spending is -458.3% of revenue (bottom 35%); a gross margin of 82.8% (top 30%); research spending of 531.8% of revenue (top 28%) (its annual report).

What it rests on

cash less debt against assets16.9%bottom 34% of its family
cash from operations less capital spending against revenue-458.3%bottom 35% of its family
gross margin82.8%top 30% of its family
research spending against revenue531.8%top 28% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

SI estimate

5.0/10

What could actually drive growth from here?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 45% of this tense · 50th percentile among 307 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending, so the desk assumes the typical reading of its industry family, the median of 307 members with one.
What the record cannot read: The record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending.
How it was reasoned: family median, 307 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Pyxis Oncology, Inc.'s growth drivers is put at 5.0 of 10 with a confidence of 20 of 100, because the record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending, so the desk assumes the typical reading of its industry family, the median of 307 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Expectations vs reality

SI estimate

5.3/10

Did its newest year beat what its own record pointed to?

SI estimate 5.3/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 234 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one.
What the record cannot read: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned: family median, 234 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Pyxis Oncology, Inc.'s expectations vs reality is put at 5.3 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton PYXS · research, not advice